Apellis Pharmaceuticals (NASDAQ:APLS) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLSFree Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $92.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC restated a buy rating and issued a $85.00 price target on shares of Apellis Pharmaceuticals in a report on Wednesday, May 8th. Mizuho lowered their target price on Apellis Pharmaceuticals from $60.00 to $52.00 and set a neutral rating on the stock in a research note on Monday, April 29th. Wedbush decreased their target price on Apellis Pharmaceuticals from $67.00 to $57.00 and set a neutral rating for the company in a research report on Wednesday, April 17th. Wells Fargo & Company decreased their price objective on Apellis Pharmaceuticals from $57.00 to $48.00 and set an equal weight rating for the company in a report on Thursday, May 23rd. Finally, Robert W. Baird restated an outperform rating and issued a $81.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of Moderate Buy and an average price target of $76.27.

Check Out Our Latest Stock Analysis on Apellis Pharmaceuticals

Apellis Pharmaceuticals Stock Down 0.9 %

Shares of NASDAQ APLS opened at $40.75 on Tuesday. Apellis Pharmaceuticals has a 52-week low of $19.83 and a 52-week high of $94.75. The company has a debt-to-equity ratio of 0.35, a quick ratio of 3.02 and a current ratio of 3.77. The company’s 50 day moving average price is $48.89 and its 200-day moving average price is $56.81. The company has a market capitalization of $4.95 billion, a P/E ratio of -11.88 and a beta of 0.97.

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.54). Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. The business had revenue of $172.33 million for the quarter, compared to analyst estimates of $163.37 million. During the same quarter in the previous year, the business earned ($1.56) earnings per share. Apellis Pharmaceuticals’s revenue for the quarter was up 284.3% on a year-over-year basis. Equities analysts forecast that Apellis Pharmaceuticals will post -1.12 earnings per share for the current year.

Insider Transactions at Apellis Pharmaceuticals

In other news, insider Pascal Deschatelets sold 78,907 shares of the stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $42.35, for a total transaction of $3,341,711.45. Following the transaction, the insider now directly owns 1,115,983 shares in the company, valued at $47,261,880.05. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 4,000 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $58.66, for a total value of $234,640.00. Following the transaction, the chief financial officer now owns 93,338 shares in the company, valued at $5,475,207.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Pascal Deschatelets sold 78,907 shares of the stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $42.35, for a total transaction of $3,341,711.45. Following the sale, the insider now directly owns 1,115,983 shares of the company’s stock, valued at $47,261,880.05. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 192,012 shares of company stock worth $9,608,319. 6.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of APLS. Comerica Bank lifted its holdings in shares of Apellis Pharmaceuticals by 500.7% during the 1st quarter. Comerica Bank now owns 8,163 shares of the company’s stock valued at $480,000 after purchasing an additional 6,804 shares during the last quarter. Tidal Investments LLC acquired a new position in Apellis Pharmaceuticals during the 1st quarter valued at about $266,000. Iron Triangle Partners LP purchased a new stake in Apellis Pharmaceuticals in the first quarter valued at about $32,329,000. Jacobs Levy Equity Management Inc. boosted its holdings in Apellis Pharmaceuticals by 4.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 20,057 shares of the company’s stock worth $1,179,000 after acquiring an additional 903 shares in the last quarter. Finally, Redmile Group LLC purchased a new stake in shares of Apellis Pharmaceuticals during the first quarter worth about $9,111,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Read More

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.